Natco Pharma

Hyderabad, India Founded: 1981 • Age: 45 yrs Listed Fortune India 500 · #485
APIs and finished dosage forms are developed and manufactured.

About Natco Pharma

Natco Pharma is a publicly listed company based in Hyderabad (India) founded in 1981 by Venkaiah Chowdary Nannapaneni. APIs and finished dosage forms are developed and manufactured. The company has 5,060 employees. Natco Pharma has completed 1 acquisition, including Dash Pharmaceuticals. Its chief executive, as recorded, is Rajeev Nannapaneni. Its website natcopharma.co.in draws about 20 thousand monthly visits. Its Indian entity Natco Pharma Limited reported revenue of β‚Ή4,376 Cr. Natco Pharma offers products and services including Generic Drugs and Active Pharmaceutical Ingredients. Its focus areas include Traditional Pharmaceuticals, Generics and Diversified.

Company details

Natco Pharma was founded in 1981 and is headquartered in Hyderabad, India. Operations are focused on the pharmaceutical sector, where active pharmaceutical ingredients and finished dosage forms are developed and manufactured. A pipeline of generic drugs is maintained, alongside a drug discovery research program in oncology. Emphasis is placed on niche therapeutic areas, complex products, contract manufacturing, and marketing of drug formulation services.

Natco Pharma is ranked #485 on the Fortune India 500 (2025).

Recognitions & Rankings of Natco Pharma

Fortune India 500 2025 edition
Rank#485
Total income
₹4,797 Cr
Profit
₹1,885 Cr
India's Most Valuable Companies 2024 edition · Source: Hurun India
Rank#223
Valuation
₹26,610 Cr
2023 #278 2022 #309 2021 #238
  • Headquarters Hyderabad, India
  • Employees 5,060
  • Founders Venkaiah Chowdary Nannapaneni
  • Stage Public
  • Sectors
    Healthcare
  • Website category Health · Biotechnology and Pharmaceuticals
  • Email
    β€’β€’β€’β€’β€’β€’β€’β€’
  • Phone
    β€’β€’β€’β€’ β€’β€’β€’β€’
  • Website natcopharma.co.in
  • Social LinkedIn X Facebook
  • Legal Name Natco Pharma Limited
Key Metrics
  • Market Cap
    ₹16,098 Cr

    NATCOPHARM · NSE

  • Share Price
    ₹821.95

    +0.16% today

  • Revenue
    ₹4,078 Cr

    FY 2025-26 · -7.9% YoY

  • EBITDA
    ₹1,436 Cr

    Margin 35.2%

  • Net Profit
    ₹1,437 Cr

    FY 2025-26 · -23.7% YoY

  • P/E (TTM)
    19.6x

    P/B 1.5x

  • ROE
    16.3%

    ROCE 17.0%

  • Debt / Equity
    0.06

    Interest cover 3.0x

  • Latest Funding Round
    $143.25M (USD), Post-IPO

    Dec 2017

  • Investors
  • Employee Count
    5,060
  • Investments & Acquisitions

Products & Services of Natco Pharma

Natco Pharma offers a comprehensive portfolio of products and services, including Generic Drugs and Active Pharmaceutical Ingredients.

Generic Drugs
Pharmaceuticals

Generic versions of oncology drugs are developed and marketed to enhance affordability in domestic and international markets

Active Pharmaceutical Ingredients
Chemical Products

Active pharmaceutical ingredients are manufactured and supplied from specialized facilities to support formulation needs

Funding Insights of Natco Pharma

  • Total Rounds 5
  • Last Round Post-IPO β€” $143.25M
  • First Round $5.5M

    (Dec 2011)

  • Investors Count 3

All 5 funding rounds of Natco Pharma with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.

DateAmountTransaction NameValuationLead InvestorsInvestors
Dec 2017$143.25MPost-IPO––
–
Oct 2017Post-IPO––
Dec 2013$18MPost-IPO––
Dec 2011$3.55MPost-IPO––
–
Dec 2011$5.5MPost-IPO––
Valuation history

3 investors in total: 3 institutional.

Investors in Natco Pharma

Natco Pharma has secured backing from 3 investors, including venture fund and institutional investors. Prominent investors backing the company include Multiples Alternate Asset Management, CX Partners and Kotak Investment Advisors.

All
Venture Fund
Institutional
InvestorDescriptionFounded YearDomainLocation
Investment partnerships, entrepreneur support, and profit-focused services in finance.
2009multiplesequity.comMumbai, India
Private equity investments in India are managed by CX Partners.
cxpartners.inDelhi, India
Provider of investment advisory services
Mumbai, India
Premium access

Investor details for Natco Pharma

The complete investor list, round-by-round participation and investor portfolios require an active premium plan.

  • Complete investor list
  • Round participation
  • Investor portfolios
  • Co-investor network

Verified entity values are shown only after access is granted.

Board of directors of Natco Pharma Limited (Natco Pharma)

Natco Pharma Limited is the primary company behind Natco Pharma. The board of Natco Pharma Limited currently have 9 directors; the longest-serving is Rajeev Nannapaneni, appointed in 2012. 20 earlier directors have ceased.

DirectorDesignationAppointedTenureEntity
Rajeev Nannapaneni
DIN 00183872
Whole-time director01 Jun 201214 yrs 5 moNatco Pharma Limited
Potluri Prasad Sivaramakrishna
DIN 07011140
Whole-time director12 Nov 201412 yrsNatco Pharma Limited
Lingarao Donthineni
DIN 07088404
Whole-time director11 Feb 201511 yrs 9 moNatco Pharma Limited
Venkaiah Chowdary Nannapaneni
DIN 00183315
Managing Director01 Apr 201511 yrs 7 moNatco Pharma Limited
Agnihotra Dakshina Murty Chavali
DIN 00374673
Director01 Apr 20242 yrs 7 moNatco Pharma Limited
Vijayabhaskar Dronadula
DIN 07158951
Director01 Apr 20242 yrs 7 moNatco Pharma Limited
Nitin Jain
DIN 00136245
Director12 Aug 20242 yrs 3 moNatco Pharma Limited
Suma Kantipudi
DIN 02734369
Director12 Aug 20242 yrs 3 moNatco Pharma Limited
Lakshminarayana Bolisetty
DIN 02766709
Director12 Aug 20242 yrs 3 moNatco Pharma Limited

People of Natco Pharma

55 people are tracked at Natco Pharma (22 in leadership, 5 in board & advisors, 28 in team); the tracked headcount is 5,060.

NameRoleGroup
Founder & Managing DirectorLeadership
CEOLeadership
Sadasiva Rao N
VP, Corporate Affairs, Legal & Secretarial, Estate ManagementLeadership
Venkat Rao Tummala
VP, Manufacturing, Chemical DivisionLeadership
Subba Rao Mente
VP, Global GenericsLeadership
Sunil Kotaru
VP, Supply Chain ManagementLeadership
Appa Rao S V V N
CFOLeadership
Ravi Kiran Namburi
VP, Marketing & Sales, DomesticLeadership
Srinivas Ch
VP, Demand & Supply PlanningLeadership
Vamsi Krishna Mutyala
Associate Vice President- CSRLeadership
Sandeep Kumar
Senior Vice PresidentLeadership
Rajneesh Kumar Sharma
Deputy General ManagerLeadership
Dr. Sashikanth Suthrapu
Deputy General ManagerLeadership
Amresh T.
Head Of LegalLeadership
Sara Narsaiah
Sales & Marketing Head, CHS Division - India 1(south & Central)Leadership
Tanmoy Mondal
Deputy General ManagerLeadership
Wahid Khan
General Manager, NDDSLeadership
Ramesh Rudraraju
DGM (multi Unit) - HR HeadLeadership
Ravinder Reddy Banala
AGM Financial Planning And Analysis | Head CommercialLeadership
Shailesh. Indulkar
Zonal Business HeadLeadership

35 more people are available in the full profile.

Premium access

Complete people profiles for Natco Pharma

Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.

  • Full employee list
  • Team structure
  • Board tenure
  • Professional contacts

Verified entity values are shown only after access is granted.

IPO & Listings of Natco Pharma

Natco Pharma is a publicly listed company on the NSE with ticker symbol NATCOPHARM in India, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.

  • IPO date27 Dec 1995
  • Listed onNSE: NATCOPHARM
  • Listed entityNATCO Pharma Limited
  • Exchange sectorHealth technology
  • ISININE987B01026
  • Share price₹788.15 (-0.13% on the day) · 2026-10-14
  • Market capitalisation₹15,489 Cr
  • Price to earnings12.4
  • EPS (diluted, trailing year)₹63.37
  • Dividend yield0.56%
  • Volume (last session)242,146

Financials of Natco Pharma

Exchange-reported figures of Natco Pharma Limited, the listed company behind Natco Pharma (NSE: NATCOPHARM).

Financial Highlights

FY 2025-26 Β· Consolidated
Revenue
₹4,078 Cr
-7.9% YoY
EBITDA
₹1,436 Cr
-34.6% YoY
Profit After Tax
₹1,437 Cr
-23.7% YoY
Net Worth
₹9,221 Cr
+21.2% YoY
Total Assets
₹10,002 Cr
+25.6% YoY
Total Debt
₹714 Cr
+155.5% YoY

Revenue vs Net Profit ₹ Cr

Margin trends

Financial summary ₹ Cr

MetricsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Income statement
Revenue4,0784,4303,9992,7071,9452,0521,915
Revenue growth-7.9%+10.8%+47.7%+39.2%-5.2%+7.2%-
EBITDA1,4362,1961,751936264606583
EBITDA margin+35.2%+49.6%+43.8%+34.6%+13.6%+29.5%+30.4%
Profit before tax1,4912,2911,674862202580569
Net profit1,4371,8841,390701137417448
Net profit margin+35.2%+42.5%+34.8%+25.9%+7.1%+20.3%+23.4%
EPS (β‚Ή)79.25105.3377.5639.199.3224.1625.32
Balance sheet
Total assets10,0027,9626,2995,1284,7764,4924,192
Net worth9,2217,6075,8534,8744,2644,1223,774
Total debt714279371167416268316
Cash & bank1,5512,17695354620628466.00
Net working capital3,4034,2802,9732,1781,9801,9341,927
Cash flow
Cash from operations1,7681,6971,21284946.50299417
Cash from investing(1,987)(1,436)(1,026)(465)4.00(107)(175)
Cash from financing298(211)(247)(363)34.80(186)(251)
ParticularsSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Revenue9677357396471,3631,3291,221475
Revenue growth (YoY)-29.0%-44.7%-39.5%+36.3%-0.6%-2.5%--
Other income52.1059.2077.8058.1010061.7066.30176
EBITDA25818612815957957154838.80
EBITDA margin+26.7%+25.4%+17.3%+24.5%+42.5%+43.0%+44.9%+8.2%
Depreciation49.2047.1050.4046.2052.4057.6098.3047.00
Interest17.6013.0010.909.5013.103.2010.204.40
Profit before tax243186144161614572506164
Tax69.8063.40(89.20)20.7095.8091.6099.9031.30
Net profit173122233140518480406132
EPS (β‚Ή)11.3111.5314.968.4628.9426.8422.707.43
MetricsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Income statement
Revenue3,5954,0943,5692,3511,7681,6541,790
Revenue growth-12.2%+14.7%+51.8%+33.0%+6.9%-7.6%-
EBITDA1,3052,1441,637845213418578
EBITDA margin+36.3%+52.4%+45.9%+35.9%+12.1%+25.3%+32.3%
Profit before tax1,3642,2261,555771156392583
Net profit1,2821,7781,309622105285462
Net profit margin+35.7%+43.4%+36.7%+26.5%+6.0%+17.2%+25.8%
EPS (β‚Ή)71.55103.3772.9934.917.6216.9626.07
Balance sheet
Total assets9,3297,6796,0334,9504,6884,4484,274
Net worth8,5537,3345,5924,7024,1924,0913,870
Total debt709275366161400256314
Cash & bank1,1871,85786541210126354.10
Net working capital2,7883,8072,7261,9461,7881,8631,888
Cash flow
Cash from operations1,7761,6621,19678457.70184422
Cash from investing(2,078)(1,444)(960)(437)(92.50)(3.20)(165)
Cash from financing302(212)(237)(347)35.60(183)(261)
ParticularsSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Revenue8545976095291,2641,1931,157408
Revenue growth (YoY)-32.4%-50.0%-47.4%+29.7%-2.2%-3.6%--
Other income40.3048.3072.9055.3093.3059.6062.10168
Total expenses638491516408712653596378
EBITDA21610692.4012055254056129.40
EBITDA margin+25.3%+17.8%+15.2%+22.7%+43.7%+45.3%+48.5%+7.2%
Depreciation44.0042.7045.6042.1048.1053.8093.7043.70
Interest15.609.609.708.3011.702.608.803.40
Profit before tax197102110125586543521150
Tax53.8027.40(99.60)18.3085.1078.8092.7025.40

Financial Statements

Figures in ₹ Cr; negatives in brackets. Updated 19 Nov 2026
ParticularsSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Revenue9677357396471,3631,3291,221475
Revenue growth (YoY)-29.0%-44.7%-39.5%+36.3%-0.6%-2.5%--
Other income52.1059.2077.8058.1010061.7066.30176
EBITDA25818612815957957154838.80
EBITDA margin+26.7%+25.4%+17.3%+24.5%+42.5%+43.0%+44.9%+8.2%
Depreciation49.2047.1050.4046.2052.4057.6098.3047.00
Interest17.6013.0010.909.5013.103.2010.204.40
Profit before tax243186144161614572506164
Tax69.8063.40(89.20)20.7095.8091.6099.9031.30
Net profit173122233140518480406132
EPS (β‚Ή)11.3111.5314.968.4628.9426.8422.707.43
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Revenue4,0784,4303,9992,7071,9452,0521,915
Revenue growth-7.9%+10.8%+47.7%+39.2%-5.2%+7.2%-
Other income29835412810599.00104107
Total expenses2,6422,2342,2471,7721,6811,4461,332
Employee cost687594525487445415375
EBITDA1,4362,1961,751936264606583
EBITDA margin+35.2%+49.6%+43.8%+34.6%+13.6%+29.5%+30.4%
Depreciation20723518716414311799.80
Interest36.7023.9019.2014.5017.7013.3021.50
Profit before tax1,4912,2911,674862202580569
Tax11940828514732.20137111
Net profit1,4371,8841,390701137417448
Net profit margin+35.2%+42.5%+34.8%+25.9%+7.1%+20.3%+23.4%
EPS (β‚Ή)79.25105.3377.5639.199.3224.1625.32
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Equity & liabilities
Share capital35.8035.8035.8036.5036.5036.5036.40
Reserves & surplus9,1857,5715,8174,8374,2274,0853,737
Shareholders' funds (net worth)9,2217,6075,8534,8744,2644,1223,774
Minority interest0.005.300.000.000.001.8011.20
Secured loans57318216774.90289128134
Unsecured loans14197.6020491.80126139182
Total debt714279371167416268316
Total liabilities10,0027,9626,2995,1284,7764,4924,192
Assets
Gross block4,2564,0163,6033,3753,1272,7022,149
Net block2,8032,6982,4912,4272,3122,0231,584
Capital work in progress29422513764.30130223518
Investments3,127474539392308304112
Inventories908766700743762798558
Sundry debtors8811,2471,189856621413551
Cash & bank balances1,5512,17695354620628466.00
Loans & advances1,1347617385506946981,122
Total current assets4,4744,9493,5802,6952,2832,1932,297
Total current liabilities1,071669607518303259370
Net working capital3,4034,2802,9732,1781,9801,9341,927
Total assets10,0027,9626,2995,1284,7764,4924,192
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Opening cash12070.4013211125.8019.8028.30
Net cash from operating activities1,7681,6971,21284946.50299417
Net cash from investing activities(1,987)(1,436)(1,026)(465)4.00(107)(175)
Net cash from financing activities298(211)(247)(363)34.80(186)(251)
Net change in cash78.9049.60(61.50)20.8085.306.00(8.50)
Closing cash1,5512,17695354620628466.00
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Growth
Sales growth-7.9%+10.8%+47.7%+39.2%-5.2%+7.2%-
EBITDA growth-34.6%+25.4%+87.2%+255.1%-56.5%+4.1%-
PBT growth-34.9%+36.9%+94.2%+326.3%-65.1%+1.9%-31.0%
Net income growth-23.7%+35.5%+98.4%+410.1%-67.1%-7.0%-
Revenue CAGR (3Y)+14.6%+31.6%+24.9%+12.2%-2.4%-2.1%-1.8%
EBITDA CAGR (3Y)+15.4%+102.8%+42.4%+17.1%-30.8%-13.3%-5.2%
Profitability & leverage
Net income margin+33.6%+42.5%+34.7%+26.4%+8.7%+21.6%+23.9%
Return on capital employed+17.0%+32.5%+29.6%+17.7%+3.8%+13.7%+14.5%
Return on net worth+16.3%+28.0%+25.9%+15.7%+3.3%+11.2%+12.6%
Debt / equity0.060.050.050.060.080.070.10
Long-term debt / equity0.010.000.000.000.000.000.00
Interest cover2.981.221.231.8814.642.724.45
Efficiency & per share
Fixed asset turnover0.991.161.150.830.670.851.00
Inventory turnover4.876.045.543.602.493.033.52
Debtors turnover3.833.643.913.673.764.263.62
EPS (β‚Ή)79.25105.3377.5639.199.3224.1625.32
Dividend per share (β‚Ή)5.006.009.505.504.505.256.75
Book value per share (β‚Ή)515.15424.97326.99267.06233.62225.84207.34
ParticularsSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Revenue8545976095291,2641,1931,157408
Revenue growth (YoY)-32.4%-50.0%-47.4%+29.7%-2.2%-3.6%--
Other income40.3048.3072.9055.3093.3059.6062.10168
Total expenses638491516408712653596378
EBITDA21610692.4012055254056129.40
EBITDA margin+25.3%+17.8%+15.2%+22.7%+43.7%+45.3%+48.5%+7.2%
Depreciation44.0042.7045.6042.1048.1053.8093.7043.70
Interest15.609.609.708.3011.702.608.803.40
Profit before tax197102110125586543521150
Tax53.8027.40(99.60)18.3085.1078.8092.7025.40
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Revenue3,5954,0943,5692,3511,7681,6541,790
Revenue growth-12.2%+14.7%+51.8%+33.0%+6.9%-7.6%-
Other income28132110585.5094.60101124
Total expenses2,2901,9501,9321,5061,5551,2361,212
Employee cost0.00515455426410380356
EBITDA1,3052,1441,637845213418578
EBITDA margin+36.3%+52.4%+45.9%+35.9%+12.1%+25.3%+32.3%
Depreciation19022017215113811598.10
Interest32.3019.6014.508.6013.3011.3020.60
Profit before tax1,3642,2261,555771156392583
Tax82.6037624913416.8082.70109
Net profit1,2821,7781,309622105285462
Net profit margin+35.7%+43.4%+36.7%+26.5%+6.0%+17.2%+25.8%
EPS (β‚Ή)71.55103.3772.9934.917.6216.9626.07
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Equity & liabilities
Share capital35.8035.8035.8036.5036.5036.5036.40
Reserves & surplus8,5177,2985,5564,6664,1554,0553,833
Shareholders' funds (net worth)8,5537,3345,5924,7024,1924,0913,870
Secured loans70627316774.90289128134
Unsecured loans2.901.5019986.20110128180
Total debt709275366161400256314
Total liabilities9,3297,6796,0334,9504,6884,4484,274
Assets
Gross block3,9943,7843,3603,1572,9782,6782,134
Net block2,6152,5172,2872,2342,1742,0061,574
Capital work in progress29322513462.80129223518
Investments3,265855742658550337191
Inventories724642597616698769524
Sundry debtors7601,1781,077793576400537
Cash & bank balances1,1871,85786541210126354.10
Loans & advances1,0767217085346746951,120
Total current assets3,7464,3983,2462,3552,0482,1262,235
Total current liabilities958591521409260263347
Net working capital2,7883,8072,7261,9461,7881,8631,888
Total assets9,3297,6796,0334,9504,6884,4484,274
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Opening cash11.205.506.905.905.107.9011.50
Net cash from operating activities1,7761,6621,19678457.70184422
Net cash from investing activities(2,078)(1,444)(960)(437)(92.50)(3.20)(165)
Net cash from financing activities302(212)(237)(347)35.60(183)(261)
Net change in cash0.305.70(1.40)1.000.80(2.80)(3.60)
Closing cash1,1871,85786541210126354.10
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Growth
Sales growth-12.2%+14.7%+51.8%+33.0%+6.9%-7.6%-
EBITDA growth-39.2%+31.0%+93.8%+296.6%-49.0%-27.8%-
PBT growth-38.7%+43.1%+101.8%+394.4%-60.3%-32.7%-31.2%
Net income growth-27.9%+35.9%+110.3%+491.1%-63.1%-38.3%-
Revenue CAGR (3Y)+15.2%+32.3%+29.2%+9.5%-3.8%-7.5%-2.9%
EBITDA CAGR (3Y)+15.6%+115.9%+57.7%+13.5%-36.1%-23.4%-5.8%
Profitability & leverage
Net income margin+35.7%+45.2%+36.6%+27.1%+7.9%+18.7%+26.5%
Return on capital employed+16.4%+32.8%+28.6%+16.2%+2.8%+9.3%+14.6%
Return on net worth+16.1%+28.6%+25.4%+14.3%+2.5%+7.8%+12.8%
Debt / equity0.060.050.050.060.080.070.09
Long-term debt / equity0.010.000.000.000.000.000.00
Interest cover2.901.020.991.2417.833.744.29
Efficiency & per share
Fixed asset turnover0.921.151.100.770.630.690.94
Inventory turnover5.266.615.883.582.412.563.47
Debtors turnover3.713.633.823.443.623.533.48
EPS (β‚Ή)71.59103.3772.9934.917.6216.9626.07
Dividend per share (β‚Ή)5.006.009.505.504.505.256.75
Book value per share (β‚Ή)477.80409.72312.42257.64229.69224.17212.61

Investments & Acquisitions by Natco Pharma

Natco Pharma has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Dash Pharmaceuticals.

Acquisitions
Company NameDescriptionDomainLocationFoundedAcquiredAmount
Advanced spectroscopic and laser instrumentation is developed for industrial applications.
dashpharm.comUpper Saddle River, United States2014Dec 2021$18M
Premium access

Complete acquisition details for Natco Pharma

Acquired stakes, deal sources and the complete acquisition history require an active premium plan.

  • Acquired stakes
  • Deal sources
  • Complete history
  • Exports

Verified entity values are shown only after access is granted.

Timeline of Natco Pharma

5 dated milestones of Natco Pharma across 40 years, from founding to its latest funding, stage changes and deals.

  1. Founded Natco Pharma is founded.
  2. IPO Lists on the stock exchange (IPO).
  3. Funding First funding round of $5.5M.
  4. Funding Latest funding round, Post-IPO, of $143.2M.
  5. Acquisition Acquires Dash Pharmaceuticals.

Web traffic of Natco Pharma

The website of Natco Pharma (natcopharma.co.in) receives about 19.8K visits a month and ranks #1,133,324 among all websites worldwide, #1,401 in Biotechnology and Pharmaceuticals.

  • Monthly visits
    19.8K

    ▼ 3.4% vs previous month

  • Unique visitors
    7.1K

    per month

  • Global rank
    #1,133,324

    among all websites

  • Category rank
    #1,401

    Health · Biotechnology and Pharmaceuticals

Similar websites

Websites whose visitors overlap most with Natco Pharma. Affinity shows how closely the audiences match.

WebsiteDomainAudience affinityMonthly visitsGlobal rankProfile
glandpharma.com
100%
8.4K#3,685,423View details
smspharma.com
91%
3K#2,783,668View details
aurobindo.com
88%
24.4K#1,029,164View details
ajantapharma.com
86%
20.1K#1,412,069View details
shanthabiotech.com
85%
View details
β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’.comβ€’β€’%β€’.β€’M#‒‒‒‒‒–
β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’.comβ€’β€’%β€’.β€’M#‒‒‒‒‒–
β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’.comβ€’β€’%β€’.β€’M#‒‒‒‒‒–
Premium access

All 34 similar websites and full traffic analytics for Natco Pharma

The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.

  • 34 similar websites
  • Audience overlap
  • Engagement analytics
  • Traffic by brand

Verified entity values are shown only after access is granted.

Top companies in Traditional Health & Nutrition

3 companies that operate in the same segment as Natco Pharma (Traditional Health & Nutrition) in India, ranked by their profile score on The Company Check.

CompanyDescriptionFoundedLocationTotal fundingRevenueEmployees
Oral solid drug delivery systems are manufactured and developed.
1985Mumbai, Maharashtra, IndiaUSD 42.49 MUSD 72.52 M1,115
Generic, semi-solid, and liquid dosage forms are manufactured.
1990Bengaluru, Karnataka, IndiaUSD 508.93 M4,050
Specialty generic pharmaceuticals and APIs are manufactured and marketed.
1983Mumbai, Maharashtra, IndiaUSD 6.44 B19,801
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track β€” from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • βœ“
    Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • βœ“
    Full access to every database India & global coverage, advanced filters and rich profile details
  • βœ“
    Always-on access from your team account Single premium plan for everything you see on the portal

Related news about Natco Pharma

NATCOPHARM: Q2 EBITDA 2.58B RUPEES VS 5.79B (YOY); Q2 EBITDA MARGIN 26.66% VS 42.49% (YOY)
Exchange Update β€’ 6 days ago
NATCOPHARM: Q2 CONS NET PROFIT 2B RUPEES VS 5.2B (YOY)
Exchange Update β€’ 6 days ago
NATCOPHARM: Q2 REVENUE 9.67B RUPEES VS 13.63B (YOY)
Exchange Update β€’ 6 days ago
Natco Pharma Limited: Launches Carboplatin Injection, A Generic Version Of Paraplatin® In The U.S. To Tackle Critical Shortage; Expected Sales Of $27.8 Million
Exchange Update β€’ 1 month ago
NATCO Pharma: Gets Approval For ₹1,279.36 Crore Rights Issue; Will Issue 1,70,58,082 Shares At ₹750 Each
Exchange Update β€’ 1 month ago
Premium access

Complete news archive for Natco Pharma

Full article history, source details, and older brand coverage require an active premium plan.

  • Full article archive
  • Source and publication date
  • Older coverage
  • Brand-specific news history

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Natco Pharma

Natco Pharma was founded in 1981 and raised its 1st funding round 30 years after it was founded.

Natco Pharma is headquartered in Hyderabad, India. It is registered at Hyderabad, Telangana, India.

Rajeev Nannapaneni is the CEO of Natco Pharma, as recorded in our data.

Natco Pharma has 5,060 employees.

The primary company behind Natco Pharma, Natco Pharma Limited, reported revenue of β‚Ή4,376 Cr for FY 2026, down 8% year on year.

Natco Pharma was founded in 1981 and is headquartered in Hyderabad, India. Operations are focused on the pharmaceutical sector, where active pharmaceutical ingredients and finished dosage forms are developed and manufactured. A pipeline of generic drugs is maintained, alongside a drug discovery research program in oncology. Emphasis is placed on niche therapeutic areas, complex products, contract manufacturing, and marketing of drug formulation services.

Natco Pharma offers Generic Drugs and Active Pharmaceutical Ingredients.

Yes, Natco Pharma is publicly traded on NSE under the ticker symbol NATCOPHARM.

Natco Pharma has made 1 acquisition, including Dash Pharmaceuticals.

Natco Pharma has 3 investors. Key investors include Multiples Alternate Asset Management, CX Partners, and Kotak Investment Advisors.

Natco Pharma operates through Natco Pharma Limited.

The legal entities of Natco Pharma currently have 11 directors, including Potluri Prasad Sivaramakrishna, Lingarao Donthineni, Venkat Ramesh Chekuri and others.

Explore millions of companies β€” effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals β€” all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available